Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer.

about

Clinicopathologic features and prognostic factors for patients with colorectal cancer who are 75 years and older.What is most relevant in preoperative rectal cancer chemoradiotherapy - the chemotherapy, the radiation dose or the timing to surgery?

P2860

Q47156783-C3939E26-E37F-4EE6-9D50-EE2AE3039F61 Q51049865-CF3848FA-2998-4C38-9F0D-C6DA28C43208

P2860

Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer.

Item

http://www.wikidata.org/entity/Q38825369

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Age-related systemic treatment ...... stases from colorectal cancer.

@en

type

Item

label

Age-related systemic treatment ...... stases from colorectal cancer.

@en

prefLabel

Age-related systemic treatment ...... stases from colorectal cancer.

@en

P1476

Age-related systemic treatment ...... stases from colorectal cancer.

@en

P2093

Agnes J van de Wouw

http://www.w3.org/2001/XMLSchema#string

Allert H Vos

http://www.w3.org/2001/XMLSchema#string

Geert-Jan Creemers

http://www.w3.org/2001/XMLSchema#string

Huub A A M Maas

http://www.w3.org/2001/XMLSchema#string

Laurens V Beerepoot

http://www.w3.org/2001/XMLSchema#string

Lieke G E M Razenberg

http://www.w3.org/2001/XMLSchema#string

Valery E P P Lemmens

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer.

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

P304

1443-1449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/0284186X.2016.1223880

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27585122

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer.

about

P2860

P2860

Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921